CardioKine Inc. Report issue

For profit Phase 1 Phase 3
Founded: Philadelphia PA United States (2003)
Status: Acquired by Cornerstone Therapeutics (2012) → now Chiesi (2014)

Organization Overview

First Clinical Trial
2007
NCT00578695
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Cardiokine Biopharma, LLC

Active Ingredients

Drugs in Phase 3 Trials (1)

lixivaptan (6 trials)

Drugs in Phase 1 Trials (1)

moxifloxacin (avelox) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Heart Failure (Phase 3)

Hyponatremia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 2